Status:
COMPLETED
Voriconazole Blood Levels and Toxicity
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Pharmacology
Eligibility:
All Genders
12+ years
Brief Summary
This study will look at how voriconazole, a drug used to treat or protect against fungal infections, affects the body. Adverse effects associated with voriconazole include skin problems and temporary ...
Detailed Description
Voriconazole (Vfend(Registered Trademark), Pfizer) has achieved common usage at the NIH (National Institutes of Health) Clinical Research Center for the treatment of fungal infections in immunosuppres...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Patients, at least 12 years old with no restriction of gender, race or disabilities, followed by the National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI) and National Heart Lung and Blood Institute (NHLBI) who begin treatment with voriconazole either oral or intravenous.
- Patients who have a previous voriconazole course at least 7 days before current course.
- EXCLUSION CRITERIA:
- Time elapsed greater than 15 days from initiation of voriconazole treatment for inpatients and greater than 30 days from initiation of voriconazole treatment for outpatients.
- Patients who the medical staffs caring for the patient not want entered into the study.
- Patients unable to give informed consent, due to the severity of their medical condition (Comatose patients, ICU patients under sedation).
Exclusion
Key Trial Info
Start Date :
January 19 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 25 2010
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT00359541
Start Date
January 19 2006
End Date
June 25 2010
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892